On December 4, 2024, Dewpoint Therapeutics Inc., the leading biotechnology company that develops therapeutics by targeting biomolecular condensates, announced that it has entered into a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC) to advance Dewpoint’s novel TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS), effective December 1, 2024.

Under the terms of the agreement, Dewpoint will receive an upfront payment and will be eligible for milestone payments based on specified near-term research and development objectives, with a total nominal deal value of up to $480 million. Upon reaching these milestones, MTPC will have an exclusive option to license the program and assume responsibility for global clinical development and commercialization. Dewpoint will also receive tiered royalties on net sales.

Wilson Sonsini Goodrich & Rosati represented Dewpoint Therapeutics in the transaction. The Wilson Sonsini team includes Farah Gerdes, Morgan Rhodes Logan, Myra Sutanto Shen, Han Shen, Tarek Helou, Matthew McDonald, and Seth Cowell.

For more information, please see Dewpoint Therapeutics's press release.